Cox regression analysis for PFS in ibrutinib-treated CLL (R/R cohort, n = 124)
| Factor . | Univariable analysis . | Multivariable analysis* . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| CD49d+† | 3.42 | 1.39-8.43 | .0075 | 3.41 | 1.32-8.79 | .0112 |
| UM IGHV | 1.94 | 0.67-5.58 | .2191 | — | — | — |
| TP53 disruption | 4.01 | 1.82-8.82 | .0006 | 3.06 | 1.34-6.97 | .0079 |
| Hemoglobin, g/L | ||||||
| <110 for women | 3.73 | 1.79-7.78 | .0004 | — | — | — |
| <120 for men | ||||||
| Rai stage III-IV | 2.87 | 1.40-5.91 | .0041 | — | — | — |
| β2M ≥5 mg/L | 1.09 | 0.44-2.68 | .8513 | — | — | — |
| LDH > ULN | 2.14 | 1.05-4.40 | .0373 | — | — | — |
| Time from last therapy <24 mo | 1.98 | 0.90-4.38 | .0907 | — | — | — |
| Lines of therapy >1‡ | 5.08 | 2.34-11.03 | <.0001 | 6.68 | 2.91-15.35 | <.0001 |
| Factor . | Univariable analysis . | Multivariable analysis* . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| CD49d+† | 3.42 | 1.39-8.43 | .0075 | 3.41 | 1.32-8.79 | .0112 |
| UM IGHV | 1.94 | 0.67-5.58 | .2191 | — | — | — |
| TP53 disruption | 4.01 | 1.82-8.82 | .0006 | 3.06 | 1.34-6.97 | .0079 |
| Hemoglobin, g/L | ||||||
| <110 for women | 3.73 | 1.79-7.78 | .0004 | — | — | — |
| <120 for men | ||||||
| Rai stage III-IV | 2.87 | 1.40-5.91 | .0041 | — | — | — |
| β2M ≥5 mg/L | 1.09 | 0.44-2.68 | .8513 | — | — | — |
| LDH > ULN | 2.14 | 1.05-4.40 | .0373 | — | — | — |
| Time from last therapy <24 mo | 1.98 | 0.90-4.38 | .0907 | — | — | — |
| Lines of therapy >1‡ | 5.08 | 2.34-11.03 | <.0001 | 6.68 | 2.91-15.35 | <.0001 |
LDH, lactose dehydrogenase.
Significant features for multivariate analysis were selected through a Cox LASSO (least absolute shrinkage and selection operator) regression, selecting variables with nonzero coefficient under the best λ selected by the model.48
CD49d+ cases were obtained by combining cases with ≥30% homogeneous CD49d expression and cases with CD49d bimodal expression.
Comparison between 1 and >1 lines of therapy.